Dendritic cells (DCs) are the most potent antigenpresenting cells and acquire cellular antigens and danger signals from dying cells to initiate antitumor immune responses via direct cell-to-cell interaction and cytokine production. The optimal forms of tumor cell death for priming DCs for the release of danger signals are not fully understood. OBP-301 (Telomelysin) is a telomerasespecific replication-competent adenovirus that induces selective E1 expression and exclusively kills human cancer cells. Here, we show that OBP-301 replication produced the endogenous danger signaling molecule, uric acid, in infected human tumor cells, which in turn stimulated DCs to produce interferon-c (IFN-c) and interleukin 12 (IL-12). Subsequently, IFN-c release upregulated the endogenous expression of the proteasome activator PA28 in tumor cells and resulted in the induction of cytotoxic T-lymphocytes. Our data suggest that virus-mediated oncolysis might be the effective stimulus for immature DCs to induce specific activity against human cancer cells.
Introduction
Dendritic cells (DCs) are the most important professional antigen-presenting cells and play a critical role in the induction of primary immune responses against tumorassociated antigens. Mature DCs express high levels of major histocompatibility complex (MHC) class I, II and co-stimulatory molecules such as CD80 and CD86, and secrete T-helper type-1 (Th1) cytokines such as interleukin (IL)-12 and interferon (IFN)-g. DCs acquire endogenous maturation stimuli from dying cells as a danger signal when they capture cellular antigens. Lack of danger signals delays maturation of DCs and causes active suppression of DCs stimulatory capacity, leading to the induction of T-cell tolerance (Steinman et al., 2000) . Shi et al. (2003) have previously identified uric acid as a novel endogenous warning molecule capable of alerting the immune system within cell lysates. The uric acid activates DCs following relocation from the inside to the outside of injured cells and converts immunity from non-protective to protective. In fact, it has been reported that uric acid levels are elevated in tumors undergoing immune rejection and that the inhibition of uric acid production delays tumor regression (Hu et al., 2004) .
Viruses have evolved to infect, replicate in and kill human cells through diverse mechanisms such as direct cell death machinery and fairly brisk immune responses. We reported previously that telomerase-specific replication-competent adenovirus (Telomelysin, , in which the human telomerase reverse transcriptase (hTERT) promoter element drives the expression of E1A and E1B genes linked with an internal ribosome entry site (IRES), induced selective E1 expression and efficiently killed human cancer cells, but not normal human fibroblasts Umeoka et al., 2004; Taki et al., 2005; Watanabe et al., 2006) . Although the precise molecular mechanism of OBP-301-induced cell death is still unclear, the process of oncolysis is morphologically distinct from apoptosis and necrosis. These findings led us to examine whether tumor cells killed by OBP-301 infection could stimulate DCs, thus enhancing the immune response.
In the present study, we compared three types of tumor preparations as a source of cell-derived antigen for the priming of DCs: virus-induced oncolysis, chemotherapeutic drug-induced apoptosis and necrosis by freeze/thaw. We also explored the cytokine signature and activating property of these cells for antitumor immune response against human cancer cells.
Results
We first examined whether OBP-301 infection affects the viability of human cancer cells using the XTT assay.
OBP-301 infection induced death of human cancer cell lines (H1299 human lung cancer and SW620 human colorectal cancer cells) in a dose-dependent manner (Figure 1 ). Although autophagy, or type II programmed cell death, partially involved in the cell death machinery triggered by OBP-301 infection, oncolytic cells are distinct from apoptotic cells (Supplementary Figure 1) .
We next examined whether OBP-301 infection modulated intracellular concentrations of uric acid that might act as a danger signal in tumor cells. Uric acid levels increased in H1299 cells following OBP-301 infection in a time-dependent fashion, although docetaxel slightly upregulated the uric acid concentration 72 h after treatment (Figure 2a) . Thus, tumor cells undergoing oncolysis can produce significantly greater amounts of uric acid when compared with apoptotic tumor cells. The uric acid elevation pattern of OBP-301-infected cells almost paralleled that of cells infected with Onyx-015, an E1B 55 kDa-deleted adenovirus engineered to selectively replicate in and lyse p53-deficient cancer cells, and wild-type adenovirus type 5 (Figure 2b ), indicating a general effect of adenovirus infection in the regulation of intracellular uric acid levels.
Uric acid is produced during the catabolism of purines and is the end product of this process. Adenoviral replication facilitates the purine catabolism to stimulate the synthesis of progeny DNA, which in turn may increase intracellular uric acid levels by the purine degradation process. In fact, OBP-301 infection significantly increased the amount of uric acid in the cells, whereas replication-deficient dl312 infection had no apparent effect on the levels of uric acid. OBP-301-induced elevation of uric acid levels could be inhibited in the presence of cidofovir (CDV), an acyclic nucleoside phosphonate having potent broad-spectrum anti-DNA virus activity (Figure 2c ). CDV has been approved for the treatment of many types of viruses including cytomegalovirus and adenovirus (Lenaerts and Naesens, 2006) . We confirmed that CDV at 100 mM could significantly inhibited replication of OBP-301 in H1299 cells by the real-time quantitative PCR analysis (Supplementary Figure 2 ). Moreover, as OBP-301 replication was attenuated in telomerase-negative cells, the levels of uric acid could not be altered in normal human lung fibroblasts (NHLF) after OBP-301 infection (Figure 2d ). These results suggest that viral replication is required to produce uric acid in infected cells.
Xanthine oxidoreductase (XOR) is a member of the molybdoflavoenzyme family that catalyses the formation of uric acid from xanthine and hypoxanthine (Glantzounis et al., 2005) . A strand-specific reverse transcriptase PCR assay demonstrated that XOR mRNA expression gradually decreased in OBP-301-infected cells presumably due to the negative feedback of increased uric acid levels, whereas docetaxel-treated cells yielded consistent bands of the XOR transcripts ( Figure 2e ). Thus, adenoviral replication could directly stimulate the catalytic DNA turnover, which enables cells to produce more uric acid.
We then examined the ability of OBP-301-infected cells to stimulate immature DCs in vitro. DCs generated from HLA-A24 þ healthy volunteers were co-cultured with HLA-matched H1299 cells (HLA-A32/A24) treated with OBP-301 or docetaxel for 72 h, or freeze thawed. The production of Th1 cytokines such as IFN-g and IL-12 in the supernatants was then explored by enzyme-linked immunosorbent assay (ELISA) analysis 48 h after the coculture. DCs incubated with OBP-301-infected cells secreted large amounts of IFN-g and IL-12, whereas stimulation with docetaxel-treated apoptotic cells induced their secretion at low levels ( Figure 3a) . The level of cytokine production from DCs incubated with freezethawed necrotic cells was similar to that of untreated immature DCs. Moreover, we confirmed that addition of OBP-301 alone without target tumor cells did not affect the cytokine secretion of DCs into the supernatant, indicating that infection of OBP-301 itself had no apparent effect on DCs. Thus, DCs stimulated with oncolytic tumor cells preferentially secrete high-level Th1 cytokines. Flow cytometry demonstrated that the increase in the expression of CD83, which is expressed on mature DCs, was slightly higher on DCs incubated with oncolytic cells than those with apoptotic or necrotic cells, indicating that oncolytic tumor cells seems to have a positive influence on DC maturation (Supplementary Figure 3) .
In the next step, we investigated the effects of oncolytic tumor cells on T-cell activation in the presence of DCs. H1299 cells were infected with OBP-301 over 72 h, and then co-incubated with HLA-matched HLA-A24 þ peripheral blood mononuclear cells (PBMCs) for another 48 h in mixed lymphocyte tumor culture (MLTC). In other tests, H1299 cells were exposed to docetaxel for 72 h or freeze thawed, and then cocultured with PBMCs. We examined the secretion of IFN-g and IL-12 into the supernatants after MLTC for 7 days. Stimulation with OBP-301-infected cells induced the secretion of high levels of IFN-g and IL-12 into MLTC supernatants, which was significantly higher Virus-mediated oncolysis Y Endo et al than that with docetaxel-treated or freeze-thawed H1299 cells ( Figure 3b ). Thus, oncolytic tumor cells can accelerate the cleavage of tumor antigen peptides that can be associated with MHC class I molecules via IFN-g secretion by immune cells. Stimulation of cells with IFN-g is known to induce the expression of PA28, a proteasome activator that accelerates the in vitro processing of MHC class I ligands from their polypeptide precursors . We investigated whether PA28 expression was upregulated in H1299 cells by adding the supernatants of co-cultures of PBMCs and OBP-301-infected H1299 cells. Western blot analysis for PA28 demonstrated that, following heat inactivation of residual OBP-301, MLTC supernatants with oncolytic tumor cells induced a strong endogenous PA28 expression in H1299 cells. In contrast, exposure to the supernatants of PBMCs alone, PBMCs with untreated H1299 cells, and PBMCs with oncolytic tumor cells without heat inactivation resulted in no apparent changes in the expression levels of PA28 (Figure 4) .
Finally, the cytotoxic T-lymphocyte (CTL) response against human cancer cells was assessed by a standard 6-h 51 Cr release assay after a 7-day MLTC using various forms of H1299 cells. The lytic activity of CTLs induced by apoptotic or necrotic H1299 cells was comparable with that of human lymphokine-activated killer (LAK) cells; CTLs stimulated with oncolytic H1299 cells, however, more efficiently killed target H1299 cells ( Figure 5 ). In contrast, LAK cells effectively lysed SW620 cells, whereas these cells were minimally killed by CTLs stimulated with apoptotic, necrotic or oncolytic H1299 cells. Furthermore, HLA-unmatched, HLA-A26/ A30 þ A549 human lung cancer cells were not sensitive to oncolytic tumor cell-induced cytotoxicity (data not shown), suggesting that effector cells stimulated with First-strand DNA generated from RNA was amplified using either the primers specific for XOR sequence or the primers that recognize b-actin sequences as an internal control.
Virus-mediated oncolysis Y Endo et al OBP-301-infected tumor cells exhibit MHC class I-restricted reactivity.
Discussion
In the present study, our goal was to determine whether oncolytic virus is effective not only as a direct cytotoxic drug but also as an immunostimulatory agent that could induce specific CTL for the remaining antigen-bearing tumor cells. Several groups have debated whether necrotic or apoptotic cells can stimulate DCs to cross-present cellderived peptides, with subsequent enhancement of tumor immunogenicity. Furthermore, it has been reported recently that the immunogenicity of tumors is not regulated by signals associated with apoptotic or necrotic cell death, but is an intrinsic feature of the tumor itself (Bartholomae et al., 2004) . Our data indicate that viral oncolysis could efficiently load tumor antigen on DCs, and then generate CTL response as judged from the production of cytokines. Moreover, the CTL activity against untreated tumor cells suggests that CTLs are specific to tumor antigens, but not to adenovirus proteins. DCs are known to ingest dying tumor cells and initiate tumor-specific responses when associated with appropriate danger signals, which are endogenous activation signals liberated by dying cells. Recent studies have shown that some intrinsic biochemical factors, such as uric acid, bradykinin and heat shock protein (HSP110) act as danger signals through their interaction with DCs, and influence the subsequent immune response (Aliberti et al., 2003; Shi et al., 2003; Manjili et al., 2005) . Large amounts of uric acid can be produced following tissue injury in vivo, and activate the immune response against injured cells and dying tissues. We found that OBP-301 infection increased intracellular uric acid levels in human tumor cells compared with apoptosis-or necrosisinducing stimuli, suggesting that viral replication itself can enhance tumorigenicity. 
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Viral oncolysis increases the immunogenicity of tumor cells presumably by the release of proinflammatory cytokines (Lindenmann and Klein, 1967) . We showed that OBP-301-infected oncolytic tumor cells efficiently stimulated immature DCs to produce greater amounts of IFN-g and IL-12 than apoptotic and necrotic cells, and that such stimulation led to DC maturation. Viral infection itself has been reported to activate DCs to secrete pro-or anti-inflammatory cytokines, which can drive DCs to undergo the maturation process (Ho et al., 2001) ; the observation that OBP-301 alone had no effect on cytokine production by DCs, however, indicates that OBP-301 itself may be less infective or stimulatory to DCs. The result is consistent with our finding that OBP-301 attenuated replication as well as cytotoxicity in human normal cells.
It will be of interest to more mechanistically define why viral oncolysis efficiently induces CTL activity against tumor cells. We hypothesized that viral replication itself or the released cytokines by immune cells positively influences tumor cell immunogenicity. The IFN-g-inducible proteasome modulator complex PA28 participates in the generation of antigenic peptides required for MHC class I antigen presentation . As expected, the supernatants of MLTC with OBP-301-infected tumor cells, in which IFN-g secretion was detected, induced a strong expression of endogenous PA28. Thus, oncolytic tumor cells can accelerate the cleavage of tumor antigen peptides that can be associated with MHC class I molecules via IFN-g secretion by immune cells. In fact, it has been reported that restoration of PA28 expression in PA28-deficient melanoma cells rescues the melanoma antigen epitope presentation ; our preliminary experiments however demonstrated that human tumor cells transfected with PA28a expression vector were less sensitive to tumor-specific CTLs (data not shown). These observations suggest that antigen peptide production alone does not seem sufficient to enhance tumor immunogenicity.
In conclusion, we provide for the first time evidence that oncolytic virus replication induces tumor-specific immune responses by stimulating uric acid production as a danger signal as well as accelerating tumor antigen cleavage by IFN-g-inducible PA28 expression. Since the induction of systemic immunity has rarely been observed in clinical trials with other conditionally replication-competent viruses, more in vivo experiments are clearly required to support the induction of antitumor immunity by OBP-301 treatment. Our data, however, suggest that the antitumor effect of OBP-301 might be potentially both direct and indirect as well as systemic rather than local.
Materials and methods

Cell lines and reagents
The human non-small lung cancer cell lines H1299 (HLA-A32/ A24) and the human colorectal carcinoma cell lines SW620 (HLA-A02/A24) were maintained in vitro in RPMI 1640 supplemented with 10% fetal calf serum, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin. Recombinant human cytokines granulocyte/macrophage colony-stimulating factor (GM-CSF), IL-4, TNF-a and IL-7 were purchased from Genzyme Cytolytic reactivity against H1299 (a) and SW620 (b) human cancer cells was assessed after 7-day mixed lymphocyte tumor culture (MLTC) with oncolytic, apoptotic or necrotic H1299 cells treated the same as above by 6-h standard 51 Cr-release assay. Lymphokine-activated killer (LAK) cells were generated from peripheral blood mononuclear cells (PBMCs) in the presence of interleukin (IL)-2 (100 U ml À1 ) for 3 days. The CTLs were compared with LAK cells and untreated PBMCs, which served as positive and negative controls, respectively. Data represent the mean7s.d. of three wells at four different effector-to-target (E/T) ratios. 
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Adenovirus
The recombinant replication-selective, tumor-specific adenovirus vector OBP-301 (Telomelysin), in which the hTERT promoter element drives the expression of E1A and E1B genes linked with an IRES, was constructed and characterized previously Umeoka et al., 2004; Taki et al., 2005; Watanabe et al., 2006) . Onyx-015 (dl1520) is an E1B 55 kDa-deleted adenovirus engineered to selectively replicate in and lyse p53-deficient cancer cells, and kindly provided by Dr Frank McCormick (UCSF Comprehensive Cancer Center and Cancer Research Institute). The E1A-deleted adenovirus vector lacking a cDNA insert (dl312) was also used as a control vector. The viruses were purified by CsCl 2 step gradient ultracentrifugation followed by CsCl 2 linear gradient ultracentrifugation.
Cell viability assay XTT assay was performed to measure cell viability. Briefly, cells were plated on 96-well plates at 5 Â 10 3 per well 24 h before treatment and then infected with OBP-301 or exposed to docetaxel. Cell viability was determined at the times indicated by using a Cell Proliferation Kit II (Roche Molecular Biochemicals) according to the protocol provided by the manufacturer.
Reverse transcription (RT)-PCR
Total RNA was isolated from mock-, OBP-301-and docetaxel-treated cells using RNAzol (Cinna/BioTecx, Friendswood, TX, USA) in a single-step phenol-extraction method and used as templates. Reverse transcription was performed at 22 1C for 10 min and then 42 1C for 20 min using 1.0 mg of RNA per reaction to ensure that the amount of amplified DNA was proportional to that of specific mRNA in the original sample. PCR was performed with specific primers in volumes of 50-ml according to the s protocol provided by the manufacturer (PCR kit; Perkin-Elmer/Cetus, Norwalk, CT, USA). The specific primers used for XOR were 5 0 -GCG AAG GAT AAG GTT ACT TGT-3 0 (forward) and 5 0 -CTC CAG GTA GAA GTG CTC TTG-3 0 (reverse); and for b-actin were 5 0 -ATG GTG GGA ATG GGT CAG AAG-3 0 (forward) and 5 0 -GCA GCT CAT TGT AGA AGG-3 0 (reverse). The reaction conditions were denaturing at 94 1C for 2 min followed by 30 cycles consisting of denaturing at 94 1C (30 s), annealing at 65 1C (15 s) and extension at 72 1C (10 s) using a thermal cycler (Perkin-Elmer, Foster City, CA, USA). The reactions were completed by a final 2-min extension at 72 1C. The PCR products were resolved on 1% agarose gels and visualized by SYBR Gold Nucleic Acid Gel Stain (Molecular Probes Inc., Eugene, OR, USA).
Preparation of tumor cells
For induction of oncolysis, tumor cells were infected with OBP-301 at a multiplicity of infection (MOI) of 1-10, and then collected 24-72 h after infection. Apoptotic tumor cells were obtained after 24-72-h exposure to 50-100 nM of docetaxel. For induction of necrosis, tumor cells suspended in phosphatebuffered saline (PBS) were subjected to rapid four freeze/thaw cycles using a 60 1C water bath and liquid nitrogen.
Measurement of uric acid concentration
Cultured cells were harvested after treatment and rinsed three times with PBS. These cells were resuspended in lysis buffer at a density of 200 Â 10 6 cells per 100 ml. The buffer contained 10 mM Tris-HCl (pH 7.5), 150 nM NaCl, 50 mM NaF, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5 mM Na 3 VO 4 , 10% glycerol, 0.5% NP-40 and 0.1 mM phenylmethylsulfonyl fluoride (PMSF). After 10-s homogenization, the resulting extracts were kept on ice for 30 min and then were centrifuged for 15 min at 2000 g. The supernatants from treated tumor cells were assayed for uric acid using Uric Acid C test (Wako, Osaka, Japan).
Preparation of DCs
Peripheral blood samples were obtained from normal HLA-A24 positive healthy volunteers and PBMC were isolated by sedimentation over Ficoll-Hypaque. They were subsequently allowed to adhere in culture flasks for 1 h at 37 1C at a density of 4.0 Â 10 7 cells per plate. Non-adherent cells in the plate were removed and the remaining (adherent) cells were cultured for 7 days in AIM-V (Gibco, Rockville, MD, USA) containing 2% heated-inactivated autologous serum supplemented with GM-CSF (50 ng ml
À1
) and IL-4 (50 ng ml
).
Cytokine production assay DCs were co-cultured with treated tumor cells at a ratio of 3:1 (DC/tumor cell) in a culture medium containing GM-CSF (50 ng ml
) and IL-4 (50 ng ml À1 ). After 24-h incubation, the supernatant was collected and stored at À80 1C until the assay. The concentrations of IFN-g and IL-12 (p40 and p70) were measured with appropriate ELISA kits (BioSource, Camarillo, CA, USA).
MLTC and CTL assay
PBMCs were co-cultured with treated tumor cells at a ratio of 20:1 in the presence of IL-2 (Roche) (10 U ml
À1
) and IL-7 (Genzyme Techne) (5 ng ml À1 ) for 7 days. Cultured cells were then used as effector cells in a standard 4 h-51 Cr release assay and the percentage of lysed cells was calculated. Percent specific lysis ¼ ((experimental cpmÀspontaneous cpm)/(maximal cpmÀspontaneous cpm) Â 100). Supernatants from MLTC performed as above were also assayed for IFN-g and IL-12 by ELISA assays (BioSource).
Western blot analysis
The primary antibodies against proteasome activator PA28 (ZMD353; Invitrogen, Carlsbad, CA, USA), actin (AC-40; Sigma Chemical Co., St. Louis, MO, USA) and peroxidaselinked secondary antibody (Amersham, Arlington Heights, IL, USA) were used. Cells were washed twice in cold PBS and collected, then lysed in lysis buffer (10 mM Tris (pH 7.5), 150 mM NaCl, 50 mM NaF, 1 mM EDTA, 10% glycerol and 0.5% NP40) containing proteinase inhibitors (0.1 mM PMSF and 0.5 mM Na 3 VO 4 ). After 20 min on ice, the lysates were spun at 14 000 rpm in a microcentrifuge at 4 1C for 10 min. The supernatants were used as whole cell extracts. Protein concentration was determined using the Bio-Rad protein determination method (Bio-Rad, Richmond, CA, USA). Equal amounts (50 mg) of proteins were boiled for 5 min and electrophoresed under reducing conditions on 6-12.5% (w/v) polyacrylamide gels. Proteins were electrophoretically transferred to a Hybond-polyvinylidene difluoride transfer membranes (Amersham Life Science, Buckinghamshire, UK), and incubated with the primary antibody, followed by peroxidase-linked secondary antibody. An Amersham ECL chemiluminescent western system (Amersham) was used to detect secondary probes.
Statistical analysis
Data are expressed as mean7s.d. The Student's t-test was used to compare differences. Statistical significance was defined when P was o0.05.
